Montelukast Sodium
C35H35ClNNaO3S
608.17
Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt, [R-,(E)]-;
Sodium 1-[[[(R)-m-[(E)-2-(7-chloro-2-quinolyl)vinyl]-α-[o-(1-hydroxy-1-methylethyl)phenethyl]benzyl]thio]-methyl]cyclopropaneacetate
[151767-02-1] C35H36ClNO3S 586.18
Montelukast [158966-92-8]
Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt, [R-,(E)]-;
Sodium 1-[[[(R)-m-[(E)-2-(7-chloro-2-quinolyl)vinyl]-α-[o-(1-hydroxy-1-methylethyl)phenethyl]benzyl]thio]-methyl]cyclopropaneacetate
[151767-02-1] C35H36ClNO3S 586.18
Montelukast [158966-92-8]
DEFINITION
Montelukast Sodium contains NLT 98.0% and NMT 102.0% of C35H35ClNNaO3S, calculated on the anhydrous and solvent-free basis.
USP REFERENCE STANDARDS FOR PURCHASE
USP Montelukast Dicyclohexylamine RSUSP Montelukast Racemate RS
USP Montelukast Sodium RS
USP Montelukast for Peak Identification RS